217302-56-2

Upstream product

• 762-42-5 dimethyl acetylenedicarboxylate 
• 217303-25-8 2-(4-benzyloxyphenyl)-8-(tert-butyldimethylsilanyloxymethyl)-1-ethylindolizine 
• 217302-97-1 dimethyl 7-benzyloxy-3-(4-benzyloxyphenyl)-4-ethylpyrrolo[2,1,5-cd]indolizine-1,2-dicarboxylate 
• 217302-98-2 7-benzyloxy-3-(4-benzyloxyphenyl)-4-ethylpyrrolo[2,1,5-cd]indolizine-1,2-dicarboxylic acid 
• 217303-23-6 3-hydroxymethyl-2-n-propylpyridine 
• 187827-12-9 ethyl (2Z)-3-aminohex-2-enoate 
• 3249-68-1 ethyl butyroyl acetate 
• 31931-49-4 ethyl 2-propylpyridine-3-carboxylate 
• 4254-67-5 2-bromo-1-(4-benzyloxyphenyl)-1-ethanone 
• 217303-24-7 1-ethyl-2-(4-benzyloxyphenyl)-8-hydroxymethylindolizine 

Downstream Products

• 217302-57-3 2-(4-benzyloxyphenyl)-1-ethyl-7-hydroxymethylpyrrolo[2,1,5-cd]indolizine 

Relevant academic research and scientific papers

Pyrrolo[2,1,5-cd]indolizine derivatives useful in the prevention or treatment of estrogen related diseases or syndromes

The present invention relates to therapeutically active compounds of formula I a method of preparing the same and to pharmaceutical compositions comprising the compounds. The novel compounds are useful in the prevention or treatment of estrogen related diseases or syndromes.

Synthesis and estrogen receptor binding affinities of novel pyrrolo[2,1,5-cd]indolizine derivatives

A series of pyrrolo[2,1,5-cd]indolizine derivatives has been synthesized and evaluated as ligands for the estrogen receptor. Properly substituted mono- and di-hydroxy derivatives showed binding in the low nanomolar range in accordance with their structural resemblance to estrogen. (C) 2000 Elsevier Science Ltd.